Christopher Halliday
Calgary, AB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Journal: Cardiovascular diabetology
Published: March 06, 2021
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
Journal: Cell
Published: October 28, 2020
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease.
Journal: Cardiovascular therapeutics
Published: April 30, 2020
Apabetalone downregulates factors and pathways associated with vascular calcification.
Journal: Atherosclerosis
Published: June 29, 2018
Benefit of Apabetalone on Plasma Proteins in Renal Disease.
Journal: Kidney international reports
Published: October 18, 2017
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.
Journal: Kidney & blood pressure research
Published: August 22, 2017
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).
Journal: Journal of cardiovascular translational research
Published: December 21, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.
Journal: Data in brief
Published: January 28, 2016
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Journal: Atherosclerosis
Published: May 21, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026